Aiman Alsaegh¹*, Amirah Qadiri², Ghaida Nojoom³, Alaa Banjar⁴ and Ramya Sindi^1,5

¹Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences Umm Al-Qura University, Makkah, Saudi Arabia
²Histopathology Department, Dr. Suliman Alhabib Hospital, Jeddah, Saudi Arabia
³Pathology Department, High Quality Lab, Makkah, Saudi Arabia
⁴Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
⁵Hekma School of Education, Health and Behavioural Sciences, Dar Al-Hekma University, Jeddah, Saudi Arabia

*Corresponding Author: Aiman Alsaegh, Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences Umm Al-Qura University, Makkah, Saudi Arabia.

Received: December 22, 2023; Published: December 28, 2023

Abstract

Colorectal cancer (CRC) is the third most common malignancy around the world. Chemotherapy, particularly 5- Fluorouracil (5-FU), is the current first-line treatment strategy for CRC. However, chemoresistance restricted the therapeutic effectiveness of 5-FU, necessitating the exploration of novel treatment protocols. A growing body of evidence supported the efficacy of coenzyme Q10 (CoQ10) as a therapeutical option for pathological disorders. The study aimed to evaluate the potential therapeutic effect of CoQ10 as single or combined with 5-FU against CRC. The HCT116 cell lines were treated with monotherapy of CoQ10, 5-FU, and combined therapy for 48 hours, prior to the cell cycle and gene expression analysis. CoQ10 monotherapy arrested the cell cycle at the Sub-G1 phase and significantly increased the expression of p27 (3-fold) and Casp-3 (2.5-fold) while downregulating survivin (2-fold) and PCNA (5.5-fold) gene activity. Marked elevation in cell counts in the S and G2/M phase was observed following both 5-FU and concomitant cotherapy (CoQ10/5-FU). A comparable effect between 5-FU and combined therapy (CoQ10/5-FU) was also observed on the expression of cell cycle regulatory molecules, cell proliferation, and apoptosis markers. CoQ10 monotherapy showed a superior therapeutic effect to 5-FU and dual therapy (CoQ10/5-FU) highlighting it as a promising complementary/alternative candidate in CRC treatment possibly through its phenolic antioxidant activity and its role in mitochondrial respiration.

 Keywords: Colorectal Cancer; Fetal Bovine Serum; World Health Organization

References

1. Stewart BW., et al. “International Agency for Research on, World cancer report. 2014, Lyon: International Agency for Research on Cancer. 630 pages: illustrations (black and white, and colour).
2. Xie YH., et al. “Comprehensive review of targeted therapy for colorectal cancer”. Signal Transduction and Targeted Therapy 1 (2020): 22.
3. Huang XM., et al. “Natural products for treating colorectal cancer: A mechanistic review”. Biomed Pharmacotherapy 117 (2019): 109142.
4. Rejhova A., et al. “Natural compounds and combination therapy in colorectal cancer treatment”. European Journal of Medicinal Chemistry 144 (2018): 582-594.
5. Singh U., et al. “Coenzyme Q10 supplementation and heart failure”. Nutrition Review6 (2007): 286-293.
6. Garrido-Maraver J., et al. “Clinical applications of coenzyme Q10”. Frontiers in Bioscience (Landmark Ed), 4 (2014): 619-633.
7. Jolliet P., et al. “Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences”. International Journal of Clinical Pharmacology and Therapeutics9 (1998): 506-509.
8. Zahrooni N., et al. “The Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Growth Factor and Serum Levels of Interleukin 6 and 8 in Women with Breast Cancer: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial”. Therapeutics and Clinical Risk Management 15 (2019): 1403-1410.
9. Can G., et al. “5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells”. Oncogene38 (2013): 4529-4538.
10. Akpinar B., et al. “Correction: 5-Fluorouracil-induced RNA stress engages a TRAIL-DISCdependent apoptosis axis facilitated by p53”. Oncotarget 44 (2016): 72380.
11. Yoshikawa R., et al. “Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy”. Cancer Research3 (2001): 1029-1037.
12. Kim EJ., et al. “Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells”. Oncotarget28 (2018): 19911-19928.
13. Blondy S., et al. “5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes”. Cancer Science 9 (2020): 3142-3154.
14. Treberg JR., et al. “Evidence for two sites of superoxide production by mitochondrial NADH-ubiquinone oxidoreductase (complex I)”. Journal of Biological Chemistry31 (2011): 27103-27110.
15. Oh HJ., et al. “p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy”. British Journal of Cancer 8 (2019): 797-805.
16. Basak D., et al. “The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)”. Cancers (Basel)11 (2020).
17. Liu Q., et al. “Modulating p-AMPK/mTOR Pathway of Mitochondrial Dysfunction Caused by MTERF1 Abnormal Expression in Colorectal Cancer Cells”. International Journal of Molecular Sciences 20 (2022).
18. Mihanfar A., et al. “Melatonin increases 5-flurouracil-mediated apoptosis of colorectal cancer cells through enhancing oxidative stress and downregulating survivin and XIAP”. Bioimpacts4 (2021): 253-261.
19. Li, J., et al. “Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2”. Frontiers in Pharmacology 12 (2021): 804265.
20. Dadali T., et al. “Elevated levels of mitochondrial CoQ (10) induce ROS-mediated apoptosis in pancreatic cancer”. Scientific Report1 (2021): 5749.
21. Oluwatosin AA. “The Effect of Dietary Co-enzyme Q10 Supplementation on Haematological Parameters and Splenic Morphology in Mouse Model of 5-FluorouracilInduced Toxicity”. Journal of Biomedical and Pharmaceutical Sciences11 (2022): 1-19.
22. Iarussi D., et al. “Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma”. Molecular Aspects of Medicine 15 (1994): s207-212.

Citation

Citation: Aiman Alsaegh., et al. “Evaluating the Therapeutic Potential of Coenzyme Q10 in Colon Cancer”.Acta Scientific Medical Sciences 8.1 (2024): 107-113.

Copyright

Copyright: © 2024 Aiman Alsaegh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.